---
title: "MTSR.US (MTSR.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MTSR.US/news.md"
symbol: "MTSR.US"
name: "MTSR.US"
parent: "https://longbridge.com/en/quote/MTSR.US.md"
datetime: "2026-03-03T15:29:52.465Z"
locales:
  - [en](https://longbridge.com/en/quote/MTSR.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MTSR.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MTSR.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/MTSR.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/MTSR.US/news.md)


# MTSR.US (MTSR.US) — Related News

### [](https://longbridge.com/en/news/275889593.md)
*2026-02-13T11:07:19.000Z*
> Documents from the U.S. Securities and Exchange Commission (SEC) show that Alphabet has completely divested its shares i

### [Chart Of The Week: How AI Is Learning To Stay On The Job](https://longbridge.com/en/news/275025381.md)
*2026-02-05T20:23:00.000Z*
> This week's chart from METR highlights the evolving capabilities of AI models, particularly in software engineering task

### [Pfizer's revenue for the fourth quarter of 2025 was $17.56 billion, with a 9% growth in non-COVID business, and the full-year revenue guidance for 2026 is $59.5-62.5 billion | Financial Report Insights](https://longbridge.com/en/news/274705077.md)
*2026-02-03T20:11:27.000Z*
> Pfizer's 2025 financial report shows that the company demonstrates resilience in its strategic transformation, with a 6%

### [Pfizer sets sights on R&D strategy amid modest FY25 results](https://longbridge.com/en/news/274787243.md)
*2026-02-03T17:59:27.000Z*
> Pfizer's FY25 results show a mixed performance with revenues of $62.6bn, meeting forecasts but reflecting a 2% decline f

### [Pfizer's performance exceeded expectations but maintains a conservative outlook for 2026](https://longbridge.com/en/news/274685327.md)
*2026-02-03T16:21:56.000Z*
> Pfizer (PFE) fell 4% in early trading on Tuesday. Despite the company exceeding expectations in the fourth quarter, sale

### [BREAKINGVIEWS-Big Pharma’s revenue hole requires a pricey fix](https://longbridge.com/en/news/273835145.md)
*2026-01-27T11:31:06.000Z*
> Big Pharma, including Pfizer and Merck, faces a $400 billion revenue loss due to patent expirations, prompting the need 

### [“Setting Up The Second Act” Stock Market (And Sentiment Results)…](https://longbridge.com/en/news/270736619.md)
*2025-12-24T14:50:53.000Z*
> The article discusses Pfizer's strategic investments and market performance, highlighting its recent acquisitions and co

### [Demand for COVID-19 drugs declines, Pfizer lowers financial forecast, stock price tumbles](https://longbridge.com/en/news/269974476.md)
*2025-12-17T07:50:49.000Z*
> Pfizer lowered its financial forecast due to a decline in demand for COVID-19 drugs and patent expirations, expecting ea

### [Pharma M&A deal value up 31% YoY in 2025YTD amid return of mega-deals](https://longbridge.com/en/news/269901217.md)
*2025-12-16T17:01:29.000Z*
> Pharmaceutical M&A deal value increased by 31% YoY in 2025 YTD, reaching $179.6 billion. Key deals included Novartis' $1